에드로포늄

콜린성 (항콜린에스테라제) 약물

에드로포늄은 속효성 주사용 항콜린에스테라제 약물로, 수의학에서는 주로 '텐실론 검사'를 통한 중증근무력증(MG)의 추정 진단에 사용됩니다. 비탈분극성 신경근 차단제의 작용을 역전시키거나 특정 상심실성 빈맥(SVT)을 치료하는 데도 사용할 수 있지만, 작용 시간이 매우 짧아 이러한 목적에는 네오스티그민과 같은 지속 시간이 더 긴 대체 약물이 더 실용적인 경우가 많습니다.

작용 기전: Edrophonium acts as a rapid, reversible inhibitor of the enzyme **acetylcholinesterase**. **Mechanism of Action:** Edrophonium briefly attaches to **acetylcholinesterase** → inhibits its hydrolytic activity → **acetylcholine** accumulates in the synaptic cleft → prolonged and increased stimulation of nicotinic and muscarinic receptors. In patients with myasthenia gravis, the sudden surge of acetylcholine temporarily overcomes the autoimmune blockade/destruction of nicotinic receptors at the neuromuscular junction, leading to a rapid (but transient) return of muscle strength. Systemically, acetylcholine accumulation also causes parasympathomimetic effects including miosis, increased intestinal muscle tone, bronchoconstriction, salivation, and bradycardia.

동물 종별 용량

Cats

Presumptive diagnosis of myasthenia gravis (MG) · 0.25 to 0.5 mg (total dose) · IV · Once · Patient is gently exercised until fatigued. Place indwelling catheter. Have atropine drawn up (0.02-0.04 mg/kg IV) in case cholinergic signs develop. Flush catheter with sterile saline, then immediately lightly exercise or encourage to rise.
Presumptive diagnosis of myasthenia gravis (MG) · 0.1 mg/kg · IV · Once · Pre-treat with atropine (0.02-0.04 mg/kg IM or SC). In affected animals, paresis should resolve within one minute and effects should last for up to 15 minutes.

Dogs

Presumptive diagnosis of myasthenia gravis (MG) · 0.1-0.2 mg/kg · IV · Once · Patient is gently exercised until fatigued. Place indwelling catheter. Have atropine drawn up (0.02-0.04 mg/kg IV) in case cholinergic signs develop. Flush catheter with sterile saline, then immediately lightly exercise or encourage to rise.
Presumptive diagnosis of myasthenia gravis (MG) · 1-10 mg (total dose) · IV · Once · Presumptive positive test results in transient improvement in clinical weakness.
Presumptive diagnosis of myasthenia gravis (MG) · 0.1-0.2 mg/kg · IV · Once · Have atropine and endotracheal tube readily available in case of overdose.
Presumptive diagnosis of myasthenia gravis (MG) · 0.1 mg/kg · IV · Once · Pre-treat with atropine (0.02-0.04 mg/kg IM or SC). In affected animals, paresis should resolve within one minute and effects should last for up to 15 minutes.

용량은 면허 수의 전문가를 위한 임상 참고 자료입니다. 항상 최신 라벨과 개별 환자에 대해 확인하십시오.

투여 경로

금기

Bronchial asthma
Mechanical urinary tract obstruction
Mechanical intestinal tract obstruction
Known hypersensitivity to the drug

이상반응

Urination
Lacrimation
Vomiting
Defecation
Bradycardia
Bronchospasm
Salivation

약물 상호작용

Atropine · Antagonizes the muscarinic effects of edrophonium. Concurrent use should be done cautiously as atropine can mask the early clinical signs of a cholinergic crisis.
Dexpanthenol · Theoretically may have additive cholinergic effects when used with edrophonium.
Digoxin · Edrophonium's cardiac effects may be increased; excessive slowing of heart rate (bradycardia) may occur.
Depolarizing Muscle Relaxants (e.g., succinylcholine, decamethonium) · Edrophonium may prolong the Phase I block of these agents.
Non-depolarizing Muscle Relaxants (e.g., pancuronium, tubocurarine, vecuronium, atracurium) · Edrophonium antagonizes the neuromuscular blocking actions of these agents.

모니터링

Cholinergic adverse effects (heart rate, respiratory rate/effort, salivation)
Improvement of paresis (for 1-15 minutes) for presumptive diagnosis of myasthenia gravis

과용량

Overdosage of edrophonium may induce a **cholinergic crisis**. **Clinical Signs of Toxicity (SLUDGE syndrome and beyond):** - **GI:** Nausea, vomiting, diarrhea, salivation - **Respiratory:** Increased bronchial secretions, bronchospasm, pulmonary edema, respiratory paralysis - **Ophthalmic:** Miosis, blurred vision, lacrimation - **Cardiovascular:** Bradycardia or tachycardia, cardiospasm, hypotension, cardiac arrest - **Musculoskeletal:** Muscle cramps, profound weakness, sweating (in animals with sweat glands) > **Treatment:** Consists of immediate respiratory and cardiac supportive therapy. Administer **atropine** IV to counteract severe muscarinic effects.

VetSheet 약물 레퍼런스는 면허 수의 전문가를 위한 임상 의사결정 보조 도구이며, 전문적 판단이나 제조사의 최신 라벨을 대신하지 않습니다.